The conversation is about the safety of Breezula compared to RU58841 for hair loss treatment. The user believes Breezula is safer but less effective than RU58841.
RU58841 users report mixed results, with some experiencing no benefits and others noting regrowth but potential side effects. Many prefer finasteride and minoxidil due to better-studied safetyprofiles.
User shares 3.5-month hair transformation using 0.5 mg Dutasteride daily and Minoxidil 2x daily. Others express amazement and discuss safetyprofiles of treatments.
The conversation discusses anticipation for CB-03-01, a potential new hair loss treatment that may be more effective and have a cleaner safetyprofile than finasteride. Users are hopeful but cautious, discussing current treatments like minoxidil, nizoral, and dermarolling, and the possibility of combining them with CB-03-01 for better results.
Hair loss treatments discussed include minoxidil, finasteride, dutasteride RU, derma rolling, pyrilutamide, cosmeRNA, hair systems, and essential oils. The user seeks information on additional treatments, safetyprofiles, and alternative options for androgenetic alopecia.
TDM-105795 showed better efficacy and safety in trials for hair loss, with a higher hair count improvement compared to GT20029 and HMI 115, but it's not as widely discussed. The user is questioning why this is the case.
The conversation is about the potential availability of GT20029 on the black market and whether users would try it. Participants advise waiting for phase 3 trial results to ensure safety and efficacy.
The discussion is about a hair loss drug called pyrilutamide. Users discuss its efficacy, safety, and expected market release around 2025-2026, with some expressing concerns about the authenticity of current market offerings.
RU58841 is discussed as a topical anti-androgen for hair loss, but its effectiveness and safety are not well-documented, leading to mixed opinions and experiences among users. Some combine it with finasteride, but concerns about side effects and lack of FDA approval limit its popularity.
The conversation is about the delay in Breezula's phase 3 trials and skepticism regarding its effectiveness compared to other treatments like RU58841 and Pyrilutamide. Some users prefer safety over effectiveness, while others express frustration with the slow progress and doubt Breezula will be a significant treatment for hair loss.
Topical finasteride is less popular due to inconvenience, cost, and availability, while oral finasteride is favored for ease and safety. Some users experience side effects with topical use, but find it effective with minoxidil, though opinions on its efficacy vary.
PP405 is a new hair growth stimulant different from Minoxidil, currently in phase 2 trials. Users discuss its potential, safety concerns, and the long wait before it might be available.
A user is considering buying RU58841 powder from Aliexpress to mix with Minoxidil for hair loss treatment. Another user warns about the safety concerns of RU58841, especially from unreliable sources, and suggests trying finasteride, oral Minoxidil, and dutasteride first.
The user is exploring hair growth stimulants other than Minoxidil, mentioning Stemoxydine, various peptides, drugs like Latanoprost and Bimatoprost, and natural remedies such as Rosemary Oil and Caffeine. They express concerns about the long-term effectiveness and safety of these alternatives and seek more information on viable options for hair regrowth.
Comparing the effectiveness of RU58841, Pyrilutamide and CB-03-01 as treatments for hair loss, with people discussing different aspects such as binding affinity, time of inhibition, safety data and cost.
Taking topical minoxidil orally for hair loss treatment, discussing safety, dosing, side effects, and FAQs. Users express concerns about safety and potential heart damage, while others share experiences and results.
User TopBack56 and friends tried pyrilutamide (KX-826) for hair loss without experiencing negative side effects. They observed fine vellus hairs but no thick hair growth yet, and plan to add GT20029 to their regime after safety trials.
The conversation discusses RU58841, a compound for hair loss treatment, which was found to be effective in a 6-month trial but was not pursued due to financial issues or marketability concerns, not safety. Some users are considering crowdfunding to release the research data, while others discuss personal experiences and safety concerns with RU58841.
Treatments for hair loss, such as Minoxidil, finasteride, RU58841 and Eucapil; the legitimacy of RU58841 products; and safety concerns related to using RU58841.
RU58841, a potential hair loss treatment, was not commercialized due to marketability issues and lack of long-term safety data. Concerns about its formulation and delivery methods further complicate its use.
The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.
Some users of RU-58841 report cardiovascular symptoms like heart palpitations and chest tightness, which may be linked to its metabolites causing lung disease. The safety of RU-58841 is uncertain due to lack of long-term data and concerns about product purity, especially from gray market sources.
A user is considering using RU58841 to treat hair loss and asks if it can be effective for 4-5 years. Some suggest starting with a lower concentration and debate the safety of RU58841 compared to approved drugs like finasteride.
The conversation is about differing experiences with finasteride for hair loss, with some users reporting side effects and others not, and the debate over the drug's safety and effectiveness. Specific treatments mentioned include finasteride, dutasteride, and topical finasteride.
A new hair loss treatment, Pyrilutamide, has been released and is claimed to be a strong anti-androgen, potentially effective when used with finasteride. However, there are mixed opinions on its effectiveness and safety, with some users skeptical and others purchasing it.
The conversation is about someone looking for specific side effects reported in clinical trials for GT20029, a hair loss treatment. No results or data were found on the clinical trials site.
The conversation discusses the effectiveness of a hair loss treatment called CB (Breezula) in comparison to Pyrilutamide, and its potential when combined with Finasteride. There is uncertainty about when or if phase 3 trials for Breezula will begin.
Hair loss treatments discussed include Minoxidil, Finasteride, and RU58841. Pyrilutamide Phase 2 results are expected in June 2022, with hopes for a better alternative to current treatments.